These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 207983

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH, Walden CE, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, Ogilvie JT, Hazzard WR.
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [Abstract] [Full Text] [Related]

  • 4. A randomized prospective study of the metabolic effects of four low-estrogen oral contraceptives.
    Briggs MH.
    J Reprod Med; 1983 Jan; 28(1 Suppl):92-9. PubMed ID: 6403706
    [Abstract] [Full Text] [Related]

  • 5. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V.
    N Engl J Med; 1990 Nov 15; 323(20):1375-81. PubMed ID: 2146499
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oral contraceptives and lipoprotein metabolism.
    Tikkanen MJ, Nikkilä EA.
    J Reprod Med; 1986 Sep 15; 31(9 Suppl):898-905. PubMed ID: 3772909
    [Abstract] [Full Text] [Related]

  • 9. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E, Mälkönen M, Manninen V.
    N Engl J Med; 1981 Mar 05; 304(10):560-3. PubMed ID: 7453723
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phytohemagglutin-induced lymphocyte transformation in oral contraceptive users.
    Keller AJ, Irvine WJ, Jordan J, Loudon NB.
    Obstet Gynecol; 1977 Jan 05; 49(1):83-91. PubMed ID: 63929
    [Abstract] [Full Text] [Related]

  • 13. Pill formulations and their effect on lipid and carbohydrate metabolism.
    Brooks PG.
    J Reprod Med; 1984 Jul 05; 29(7 Suppl):539-46. PubMed ID: 6481707
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition.
    Down RH, Whiting MJ, Watts JM, Jones W.
    Gut; 1983 Mar 05; 24(3):253-9. PubMed ID: 6826111
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive.
    Batzer FR.
    J Reprod Med; 1984 Jul 05; 29(7 Suppl):503-12. PubMed ID: 6237195
    [Abstract] [Full Text] [Related]

  • 19. The Royal College of General Practitioners' Oral Contraception Study: some recent observations.
    Kay CR.
    Clin Obstet Gynaecol; 1984 Dec 05; 11(3):759-86. PubMed ID: 6509858
    [Abstract] [Full Text] [Related]

  • 20. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
    Connelly PW, Stachenko S, MacLean DR, Petrasovits A, Little JA.
    Can J Cardiol; 1999 Apr 05; 15(4):419-27. PubMed ID: 10322251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.